Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Active Psoriatic Arthritis
NCT07871721Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Jan 2027
- Primary completion
- Apr 2030
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Zasocitinib QD with Placebo QD -> Zasocitinib QD (2 arms). Primary endpoint: American College of Rheumatology 20 Response at 24 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07871721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871721.